

Dear Editor,

thank you for allow us to review this manuscript entitled: **Gastric cancer: the times they are a changin'**

I enclosed the conflict of interest statement

I made the audio core tip

All the corrections, according to the first reviewer requests, are in blue in the text

1. In the CYTOTOXIC CHEMOTHERAPY section, the authors mentioned RAINBOW trials in the last paragraph. They mentioned this study using docetaxel, however, not docetaxel but paclitaxel. The authors should revise this sentence.

- I corrected the mistake in the text

2. In ANGIOGENESIS INHIBITORS section, the authors mentioned apatinib which is selective VEGFR-2 tyrosine kinase inhibitor. In ASCO 2014, the results of phase 3 trial comparing BSC with apatinib were already reported. The newest data is better.

-

I reported the study in the text. (ref 89)

3. In HGF-c-MET AXIS section, the authors mentioned RILOMET-1 study and MetMAb. These two phases 3 studies were already reported in ASCO 2015. These were negative studies. The newest data is better.

- I agree with the reviewer, but these data were not available at time of writing. Now I inserted them in the text. (ref97)

4. In IMMUNOTHERAPY section, the results of KEYNOTE-012 study is mentioned. In ASCO 2015, the updated data of median OS was reported (11.4 mo). Could the authors revise the data?

- The data were not available at time of writing, now I updated them. (ref 125-126).

5. By searching "Clinicaltrials.gov", two on-going phase 3 studies are hit. One is KEYNOTE-061 trial (NCT02370498) which compares pembrolizumab with paclitaxel as second-line setting. Another one is nivolumab vs. BSC as the last-line (NCT02267343).

- There are many studies with immunotherapy drugs, I agree with you citing the phase III studies in the text.